Indian pharmaceuticals company Cadila Healthcare has received US Food and Drug Administration (USFDA) approval to market Benazepril tablets 5, 10, 20 and 40 mg in the US.


</p><tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The drug falls in the cardiovascular segment and the combined sales of all the strengths as per NDC was estimated at USD 301 million in 2007. This marks the 38th Abbreviated New Drug Application (ANDA) approval for the group. </P>
</p><p class='TableClas'>So far the company has filed 78 ANDAs.</P></p></table>


Cadila Healthcare receives USFDA approval

Also Read

Reliance Globalcom acquires VANCO Group

Knitwear-exporter Venus gets Wal-Mart Award

MTN advises shareholders to exercise caution

Popley Group to launch Disney Fine Jewellery

Bartronics deploys RFID wrist band in US

Explore News